0000000000123065

AUTHOR

R. Agueli

showing 6 related works from this author

Cetuximab: clinical results in colorectal cancer

2007

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineHumansEpidermal growth factor receptorNeoplasm MetastasisRandomized Controlled Trials as TopicChemotherapyCetuximabbiologybusiness.industryAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimendigestive system diseasesSurgeryRadiation therapyClinical trialClinical PracticeClinical Trials Phase III as TopicOncologybiology.proteinColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Cetuximab in squamous cell head and neck carcinomas.

2007

The epidermal growth factor receptor (EGFR) antagonist, cetuximab, has recently been shown to enhance the effects of radiotherapy, and reports to date indicate that this effect occurs without any change in the pattern and severity of toxicity usually associated with head and neck radiation and/or chemotherapy (CT) administration. Moreover, several studies have reported that the expression of EGFR is strongly linked to poor outcome in patients undergoing therapy. Therefore, the presence of the EGFR in almost all cases of head and neck carcinoma offers a new therapeutic opportunity to most patients. In this paper, we report a review of the major studies dealing with the use of cetuximab in ad…

Oncologymedicine.medical_specialtyRadiation-Sensitizing Agentsmedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineCarcinomaAnimalsHumansEpidermal growth factor receptorSquamous epithelial cellCetuximabbiologyClinical Trials Phase I as Topicbusiness.industryHead and neck cancerAntibodies MonoclonalHematologymedicine.diseaseHead and neck squamous-cell carcinomaChemotherapy regimenRadiation therapyneck carcinomasmedicine.anatomical_structureOncologyHead and Neck Neoplasmsbiology.proteinCarcinoma Squamous CellNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

2006

Pathologymedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentPlatinum Compounds.Medical OncologyCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansLung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryRespiratory diseasePlatinum compoundsHematologyPrognosismedicine.diseaseCarboplatinOncologychemistryCancer researchNon small cellCisplatinbusinessmedicine.drug
researchProduct

Is oral metronomic cyclophosphamide (CTX) an effective palliative treatment for patients with metastatic breast carcinoma (ABC)? experience from a re…

2008

OncologyCancer ResearchSeries (stratigraphy)medicine.medical_specialtyOncologyPalliative treatmentbusiness.industryInternal medicinemedicineMetastatic Breast CarcinomabusinessMetronomic cyclophosphamideEuropean Journal of Cancer Supplements
researchProduct

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safet…

2007

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) …

AdultMalemedicine.medical_specialtyPancreatic diseaseOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinAdenocarcinomaInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedRetrospective StudiesChemotherapyPerformance statusbusiness.industryCancerHematologyMiddle Agedmedicine.diseaseChemotherapy regimenGemcitabineDrug Resistance MultipleSurgeryPancreatic NeoplasmsFOLFOX4 regimen pancreatic carcinoma second-line chemotherapyRegimenOncologyChemotherapy AdjuvantDrug Resistance NeoplasmFemaleFluorouracilbusinessmedicine.drug
researchProduct

Chemotherapy for endometrial carcinoma.

2005

researchProduct